Prognostic impact of adenomatous polyposis coil gene expression in osteosarcoma of the extremities


Autoria(s): GUIMARAES, Andrea Paiva Gadelha; ROCHA, Rafael Malagoli; CUNHA, Isabela Werneck da; GUIMARAES, Gustavo Cardoso; CARVALHO, Andre Lopes; CAMARGO, Beatriz de; LOPES, Ademar; SQUIRE, Jeremy Andrew; SOARES, Fernando Augusto
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2010

Resumo

Purpose: To evaluate the impact of adjuvant chemotherapy on the outcome of osteosarcoma of the extremities, and to identify prognostic factors using the expression of adenomatous polyposis coli (APC), cadherin and beta-catenin Wnt-signalling markers. Methods: The clinical, demographic, anatomic and pathological factors including a detailed analysis of the immunohistochemical expression of cadherin, B-catenin and APC were retrospectively examined in 97 patients with osteosarcoma of the extremities (metastatic and non-metastatic at diagnosis), treated with surgery and/or chemotherapy from 1985 to 2000. Results: APC immunoreactivity showed a statistically significant association with age and serum alkaline phosphatase levels (p = 0.025 and p = 0.038). When survival was the end-point of multivariate analysis, race segregated patients with poor survival as did lack of cadherin expression. For overall survival, cadherin immunoreactivity and the interaction between APC expression and response to adjuvant chemotherapy were significant (p = 0.012 and p < 0.001). No significant clinical association was evident with immunohistochemical expression of cadherin, beta-catenin. Conclusion: Lack of expression of cadherin was a significant variable to overall and disease-free survival. Significantly, positive APC immunoreactivity and adjuvant chemotherapy were associated with a favourable treatment response. Studies using newer immunohistochemical markers within the Wnt-signalling pathway may guide the development of more appropriate therapeutic targets for future individualised treatment. (C) 2010 Elsevier Ltd. All rights reserved.

Identificador

EUROPEAN JOURNAL OF CANCER, v.46, n.18, p.3307-3315, 2010

0959-8049

http://producao.usp.br/handle/BDPI/25675

10.1016/j.ejca.2010.06.004

http://dx.doi.org/10.1016/j.ejca.2010.06.004

Idioma(s)

eng

Publicador

ELSEVIER SCI LTD

Relação

European Journal of Cancer

Direitos

restrictedAccess

Copyright ELSEVIER SCI LTD

Palavras-Chave #Cadherin #beta-Catenin #Adenomatous polyposis coli #Osteosarcoma #HIGH-GRADE OSTEOSARCOMA #HIGH-DOSE METHOTREXATE #BETA-CATENIN #NONMETASTATIC OSTEOSARCOMA #NEOADJUVANT CHEMOTHERAPY #HISTOLOGIC RESPONSE #OSTEOGENIC-SARCOMA #DOXORUBICIN #METASTASIS #CISPLATIN #Oncology
Tipo

article

original article

publishedVersion